Screener
Relmada Therapeutics, Inc. RLMD Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(19,051,956) | $(17,559,465) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 956,186 | 3,572,769 |
| Stock appreciation rights compensation | 2,677,652 | 3,038 |
| Issuance of restricted common stock | - | 905,226 |
| Realized loss/(gain) on short-term investments | 9,867 | (62,952) |
| Unrealized loss/(gain) on short-term investments | 540,097 | (155,731) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s stock-based comp?
- Relmada Therapeutics, Inc. (RLMD) reported stock-based comp of $956.19K in Q1 2026.
- How has Relmada Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Relmada Therapeutics, Inc.'s stock-based comp decreased by 73.2% year-over-year, from $3.57M to $956.19K.
- What is the long-term trend for Relmada Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s stock-based comp has grown at a -23.4% compound annual growth rate (CAGR), from $40.49M to $13.91M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Relmada Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude